Literature DB >> 19094832

Is botulinum toxin useful in treating headache? Yes.

Avi Ashkenazi1, Stephen Silberstein.   

Abstract

Recent scientific data support an effect of botulinum neurotoxin (BoNT) on pain and headache. BoNT was shown to affect the release of neurotransmitters that are important in pain transmission and in migraine pathogenesis. Data from both animal and clinical studies suggest that the toxin may have an analgesic effect that is independent from its effect on muscle tone. The high tolerability and long duration of action of the drug make it appealing as a potential prophylactic treatment for headache patients. Results of controlled trials on the efficacy of BoNT in the treatment of episodic migraine (EM) are mostly negative, although some subgroups of patients (eg, those with high attack frequency) may respond to the drug. Studies of patients with chronic daily headache have been inconclusive, although (as with the EM studies) specific subgroups of patients appear to benefit from the drug. BoNT is probably ineffective for the treatment of chronic tension-type headache. There are anecdotal reports on a positive effect of BoNT in patients with other types of headache (eg, nummular headache). Factors that may affect the response of patients to BoNT include headache characteristics, disease duration, the use of concurrent preventive medications, and the presence or absence of medication overuse. The authors' clinical experience shows that some headache patients benefit significantly from BoNT treatment. The challenge for future studies is to identify those patients who will best respond to the drug.

Entities:  

Year:  2009        PMID: 19094832     DOI: 10.1007/s11940-009-0003-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  38 in total

1.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors:  M J Welch; J R Purkiss; K A Foster
Journal:  Toxicon       Date:  2000-02       Impact factor: 3.033

Review 2.  Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins.

Authors:  Oliver Dolly
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

3.  Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.

Authors:  S Evers; J Vollmer-Haase; S Schwaag; A Rahmann; I-W Husstedt; A Frese
Journal:  Cephalalgia       Date:  2004-10       Impact factor: 6.292

4.  Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls.

Authors:  E Loder; R Goldstein; D Biondi
Journal:  Cephalalgia       Date:  2005-02       Impact factor: 6.292

5.  Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.

Authors:  S D Silberstein; H Göbel; R Jensen; A H Elkind; R Degryse; J M C M Walcott; C Turkel
Journal:  Cephalalgia       Date:  2006-07       Impact factor: 6.292

6.  Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Stuart R Stark; Sylvia M Lucas; Suzanne N Christie; Ronald E Degryse; Catherine C Turkel
Journal:  Mayo Clin Proc       Date:  2005-09       Impact factor: 7.616

7.  Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors:  Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

8.  Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.

Authors:  W J Binder; M F Brin; A Blitzer; L D Schoenrock; J M Pogoda
Journal:  Otolaryngol Head Neck Surg       Date:  2000-12       Impact factor: 3.497

9.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

10.  Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Authors:  Sheena K Aurora; Marek Gawel; Jan L Brandes; Suriani Pokta; Amanda M Vandenburgh
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

View more
  1 in total

Review 1.  Management of headache in the elderly.

Authors:  Matthew S Robbins; Richard B Lipton
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.